Is estrogen a therapeutic target for glaucoma?

Seminars in Ophthalmology

Volumn 31, Issue 1-2, 2016, Pages 140-146

  Dewundara, Samantha S ^a   Wiggs, Janey L ^a   Sullivan, David A ^a,b   Pasquale, Louis R ^a,c  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Estrogen; Glaucoma; Optic nerve degeneration; Postmenopausal hormones; Reproductive hormones; Sex differences

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN; NITRIC OXIDE; PROGESTERONE;

DRUG EXPOSURE; ESTROGEN METABOLISM; HUMAN; INTRAOCULAR PRESSURE; MEDLINE; MENARCHE; MENOPAUSE; MOLECULAR PATHOLOGY; ONSET AGE; OPEN ANGLE GLAUCOMA; ORAL CONTRACEPTION; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; THIRD TRIMESTER PREGNANCY; DRUG EFFECTS; ESTROGEN THERAPY; FEMALE; GLAUCOMA, OPEN-ANGLE; OPTIC NERVE DISEASES; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY;

ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MENOPAUSE; OPTIC NERVE DISEASES; PREGNANCY;

EID: 84962187948     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2015.1114845     Document Type: Review

References (84)

1. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology 2014;121(11):2081-2090.
2. Schmidt KG, Bergert H, Funk RH. Neurodegenerative diseases of the retina and potential for protection and recovery. Curr Neuropharmacol 2008;6:164-178.
3. Yucel YH, Zhang Q, Weinreb RN, et al. Effects of retinal ganglion cell loss on magno-, parvo-, koniocellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma. Prog Retin Eye Res 2003;22:465-481.
4. Mukesh BN, McCarty CA, Rait JL, Taylor HR. Five-year incidence of open-angle glaucoma: The visual impairment project. Ophthalmology 2002;109(6):1047-1051.
5. Vajaranant TS, Pasquale LR. Estrogen deficiency accelerates aging of the optic nerve. Menopause 2012;19(8):942-947.
6. Akar Y, Yucel I, Akar ME, et al. Menstrual cycle-dependent changes in visual field analysis of healthy women. Ophthalmologica 2005;219(1):30-35.
7. Yucel I, Akar ME, Dora B, et al. Effect of the menstrual cycle on standard achromatic and blue-on-yellow visual field analysis of women with migraine. Can J Ophthalmol 2005;40(1):51-57.
8. Akar ME1, Taskin O, Yucel I, Akar Y. The effect of the menstrual cycle on optic nerve head analysis in healthy women. Acta Ophthalmol Scand 2004; 82(6):741-745.
9. Guyton AC. Textbook of Medical Physiology Philadelphia, PA: W. B. Saunders Company, 1991.
10. Luu-The V, Labrie F. The intracrine sex steroid biosynthesis pathways. Prog Brain Res 2010;181:177-192.
11. Labrie F. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause. J Steroid Biochem Mol Biol 2015;145: 133-138.
12. Starka L, Obenberger J. In vitro estrone-estradiol-17A interconversion in the cornea, lens, iris and retina of the rabbit eye. Albrecht v Graefes Archiv Klin Exp Ophthal 1975; 196:199-204.
13. Starka L, Obenberger J. Steroids and intraocular pressure. J Steroid Biochem 1976;7:979-983.
14. Coca-Prados M, Ghosh S, Wang Y, et al. Sex steroid hormone metabolism takes place in human ocular cells. J Steroid Biochem Mol Biol 2003;86(2):207-216.
15. Kumar V, Green S, Stack G, et al. Functional domains of the human estrogen receptor. Cell 1987;51:941-951.
16. Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997;277:1508-1510.
17. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138:863-870.
18. Sullivan DA. Tearful relationships Sex, hormones and aqueous-deficient dry eye. Ocular Surface 2004;2:92-123.
19. Wickham LA, Gao J, Toda I, et al. Identification of androgen, estrogen and progesterone receptor mRNAs in the eye. Acta Ophthalmol. Scand 2000;78:146-153.
20. Kobayashi K, Kobayashi H, Ueda M, Honda Y. Estrogen receptor expression in bovine and rat retinas. Invest Ophthalmol Vis Sci 1998;39:2105-2510.
21. Munaut C, Lambert V, Noel A, et al. Presence of oestrogen receptor type beta in human retina. Br J Ophthalmol 2001; 85(7):877-882.
22. Hewitt SC, Deroo BJ, Korach KS. Signal transduction. A new mediator for an old hormone? Science 2005;307: 1625-1630.
23. Micevych P, Kuo J, Christensen A. Physiology of membrane oestrogen receptor signalling in reproduction. J Neuroendocrinol 2009;21:249-256.
24. Hammes SR, Levin ER. Minireview: recent advances in extranuclear steroid receptor actions. Endocrinology 2011; 152:4489-4495.
25. Soltysik K, Czekaj P. Membrane estrogen receptors-Is it an alternative way of estrogen action? J Physiol Pharmacol 2013;64:129-142.
26. Renoir J-M, Marsuad V, Lazennec G. Estogen receptor signaling as a target for novel breast cancer therapeutics. Biochem Pharmacol 2013;85:449-465.
27. Quereshi IA, Xi XR, Wu XD, et al. Variations in ocular pressure during the menstrual cycle. J Pak Med Assoc 1998; 48:37-40.
28. Green K, Cullen PM, Phillips CI. Aqueous humour turnover and intraocular pressure during menstruation. Br J Ophthalmol 1984;68:736-740.
29. Vaid RL, Buchh H, Ahuja L. Intraocular pressure during normal menstrual cycle. East Arch Ophthalmol 1975;3: 59-62.
30. Lee AJ, Mitchell P, Rochtchina E, Healey PR. Blue Mountains Eye Study. Female reproductive factors and open angle glaucoma: The Blue Mountains Eye Study. Br J Ophthalmol 2003;87(11):1324-1328.
31. Pasquale LR, Kang JH. Female reproductive factors and primary open-angle glaucoma in the Nurses' Health Study. Eye (Lond) 2011;25(5):633-641.
32. Hulsman CA, Westendorp IC, Ramrattan RS, et al. Is open-angle glaucoma associated with early menopause? The Rotterdam Study. Am J Epidemiol 2001; 154(2):138-144.
33. Pasquale LR, Rosner BA, Hankinson SE, Kang JH. Attributes of female reproductive aging and their relation to primary open-angle glaucoma: A prospective study. J Glaucoma 2007;16(7):598-605.
34. Nirmalan PK, Katz J, Robin AL, et al. Female reproductive factors and eye disease in a rural South Indian population: The Aravind Comprehensive Eye Survey. Invest Ophthalmol Vis Sci 2004;45(12):4273-4276.
35. Vajaranant TS, Grossardt BR, Maki PM, et al. Risk of glaucoma after early bilateral oophorectomy. Menopause 2014;21(4):391-398.
36. Phillips CI, Gore SM. Ocular hypotensive effect of late pregnancy with and without high blood pressure. Br J Ophthalmol 1985;69(2):117-119.
37. Qureshi IA, Xi XR, Wu XD. Intraocular pressure trends in pregnancy and in the third trimester hypertensive patients. Acta Obstet Gynecol Scand 1996;75(9):816-819.
38. Qureshi IA. Intraocular pressure: Association with menstrual cycle, pregnancy and menopause in apparently healthy women. Chin J Physiol 1995;38(4):229-234.
39. Erratum: Chin J Physiol 1996;39:1-63.
40. Green K, Phillips CI, Cheeks L, Slagle T. Aqueous humor flow rate and intraocular pressure during and after pregnancy. Ophthalmic Res 1988;20(6):353-357.
41. Weinreb RN, Lu A, Beeson C. Maternal corneal thickness during pregnancy. Am J Ophthalmol 1988;105(3):258-260.
42. Wilke K. Episcleral venous pressure and pregnancy. Acta Ophthalmol Suppl 1975;125:40-41.
43. Affinito P, Di Spiezio Sardo A, Di Carlo C, et al. Effects of hormone replacement therapy on ocular function in postmenopause. Menopause 2003;10:482-487.
44. Altintąs O, Caglar Y, Yuksel N, et al. The effects of menopause and hormone replacement therapy on quality and quantity of tear, intraocular pressure and ocular blood flow. Ophthalmologica 2004;218:120-129.
45. Coksuer H, Ozcura F, Oghan F, et al. Effects of estradiol-drospirenone on ocular and nasal functions in postmenopausal women. Climacteric 2011;14:482-4487.
46. Sator MO, Joura EA, Frigo P, et al. Hormone replacement therapy and intraocular pressure. Maturitas 1997;28: 55-58.
47. Tint NL, Alexander P, Tint KM, et al. Hormone therapy and intraocular pressure in nonglaucomatous eyes. Menopause 2010;17:157-160.
48. Treister G, Mannor S. Intraocular pressure and outflow facility. Effect of estrogen and combined estrogenprogestin treatment in normal human eyes. Arch Ophthalmol 1970;83:311-318.
49. Uncu G, Avci R, Uncu Y, et al. The effects of different hormone replacement therapy regimens on tear function, intraocular pressure and lens opacity. Gynecol Endocrinol 2006;22:501-505.
50. Abramov Y, Borik S, Yahalom C, et al. Does postmenopausal hormone replacement therapy affect intraocular pressure? J Glaucoma 2005;14(4):271-275.
51. Guaschino S, Grimaldi E, Sartore A, et al. Visual function in menopause: The role of hormone replacement therapy. Menopause 2003;10(1):53-57.
52. Toker E, Yenice O, Temel A. Influence of serum levels of sex hormones on intraocular pressure in menopausal women. J Glaucoma 2003;12(5):436-440.
53. Newman-Casey PA, Talwar N, Nan B, et al. The potential association between postmenopausal hormone use and primary open-angle glaucoma. JAMA Ophthalmol 2014; 132(3):298-303.
54. Pasquale LR, Loomis SJ, Weinreb RN, et al. Estrogen pathway polymorphisms in relation to primary open angle glaucoma: An analysis accounting for gender from the United States. Mol Vis 2013;19:1471-1481.
55. Ball P, Knuppen R. Catecholoestrogens (2-and 4-hydroxyoestrogens): chemistry, biogenesis, metabolism, occurrence and physiological significance. Acta Endocrinol Suppl (Copenh) 1980;232:1-127.
56. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
57. Fuchsjager-Mayrl G, Wally B, Georgopoulos M, et al. Ocular blood flow and systemic blood pressure in patients with primary open-angle glaucoma and ocular hypertension. Invest Ophthalmol Vis Sci 2004;45:834-839.
58. Feke GT, Pasquale LR. Retinal blood flow response to posture change in glaucoma patients compared with healthy subjects. Ophthalmology 2008; 115: 246-252.
59. Tunny TJ, Richardson KA, Clark CV. Association study of the 50 flanking regions of endothelial-nitric oxide synthase and endothelin-1 genes in familial primary open-angle glaucoma. Clin Exp Pharmacol Physiol 1998;25:26-29.
60. da Silva TM, Rocha AV, Lacchini R, et al. Association of polymorphisms of endothelial nitric oxide synthase (eNOS) gene with the risk of primary open angle glaucoma in a Brazilian population. Gene 2012;502(2):142-146.
61. Liao QO, Wang DH, Sun HJ. Association of genetic polymorphisms of eNOS with glaucoma. Mol Vis 2011; 17(17-20):153-158.
62. Logan JF, Chakravarthy U, Hughes AE, et al. Evidence for association of endothelial nitric oxide synthase gene in subjects with glaucoma and a history of migraine. Invest Ophthalmol Vis Sci 2005;46:3221-6.
63. Ayub H, Khan MI, Micheal S, et al. Association of eNOS and HSP70 gene polymorphisms with glaucoma in Pakistani cohorts. Mol Vis 2010;16(2-3):18-25.
64. Kang JH, Wiggs JL, Rosner BA, et al. The relation between endothelial nitric oxide synthase gene variants and primary open-angle glaucoma: interactions with gender and postmenopausal hormone use. Invest Ophthalmol Vis Sci 2010;51:971-979.
65. Emam WA, Zidan HE, Abdulhalim BE, et al. Endothelial nitric oxide synthase polymorphisms and susceptibility to high-tension primary open-angle glaucoma in an Egyptian cohort. Mol Vis 2014;20:804-811.
66. Chambliss KL, Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 2002;23:665-686.
67. Buys ES, Ko YC, Alt C, et al. Soluble guanylate cyclase b1-deficient mice: A novel murine model for primary open angle glaucoma. PLoS One 2013;8(3):e60156.
68. Kang JH1, Wiggs JL, Haines J, et al. Reproductive factors and NOS3 variant interactions in primary open-angle glaucoma. Mol Vis 2011;17:2544-2551.
69. Russo R, Cavaliere F, Watanabe C, et al. 17Beta-estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat. Prog Brain Res 2008;173: 583-590.
70. Tatrai KP, Xin H, Nguyen V, et al. 17b-Estradiol eye drops protect the retinal ganglion cell layer and preserve visual function in an in vivo model of glaucoma. Mol Pharm 2013; 10(8):3253-3261.
71. Bigsby RM, Cardenas H, Caperell-Grant C, Grubbs CJ. Protective effects of estrogen in a rat model of age-related cataracts. Proc Natl Acad Sci USA 1999;96:9328-9332.
72. Yamashita H, Sugihara K, Yamada C, et al. Effect of estrogen on electroretinographic responses in streptozotocin-induced diabetic female rats. Exp Eye Res 2010;90: 591-597.
73. Kaarniranta K, Machalinska A, Veréb Z, et al. Estrogen signalling in the pathogenesis of age-related macular degeneration. Curr Eye Res 2015;40(2):226-233.
74. Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. JAMA 2001;286:2114-2119.
75. Bourque M, Dluzen DE, Di Paolo T. Neuroprotective actions of sex steroids in Parkinson's disease. Front Neuroendocrinol 2009;30:142-157.
76. Pike CJ, Carroll JC, Rosario ER, Barron AM. Protective actions of sex steroid hormones in Alzheimer's disease. Front Neuroendocrinol 2009;30(2):239-258.
77. Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity. Brain Res 2011;1379:188-198.
78. Scott E, Zhang QG, Wang R, et al. Estrogen neuroprotection and the critical period hypothesis. Front Neuroendocrinol 2012;33(1):85-104.
79. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: A randomized controlled trial. JAMA 2011;305:1305-1314.
80. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: A randomized trial. JAMA 2003;289: 2673-2684.
81. Harman SM, Brinton EA, Clarkson T, et al. Is the WHI relevant to HRT started in the perimenopause? Endocrine 2004;24:195-202.
82. Gadducci A, Cosio S, Genazzani AR. Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body. Curr Opin Invest Drugs 2004;5(10):1031-1044.
83. Paganini-Hill A, Clark LJ. Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2000;60(2):167-172.
84. Advani P, Moreno-Aspitia A. Current strategies for the prevention of breast cancer. Breast Cancer (Dove Med Press) 2014;6:59-71.